IN2014MN02461A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02461A IN2014MN02461A IN2461MUN2014A IN2014MN02461A IN 2014MN02461 A IN2014MN02461 A IN 2014MN02461A IN 2461MUN2014 A IN2461MUN2014 A IN 2461MUN2014A IN 2014MN02461 A IN2014MN02461 A IN 2014MN02461A
- Authority
- IN
- India
- Prior art keywords
- protein aggregation
- diseases
- stress
- ledgf peptides
- ledgf
- Prior art date
Links
- 238000009472 formulation Methods 0.000 abstract 2
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000004845 protein aggregation Effects 0.000 abstract 2
- 230000004637 cellular stress Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649847P | 2012-05-21 | 2012-05-21 | |
| PCT/US2012/065620 WO2013074988A1 (en) | 2011-11-17 | 2012-11-16 | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
| PCT/US2013/042074 WO2013177198A1 (en) | 2012-05-21 | 2013-05-21 | Ledgf peptides and formulations thereof for treatment of degenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02461A true IN2014MN02461A (enExample) | 2015-07-10 |
Family
ID=49624295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2461MUN2014 IN2014MN02461A (enExample) | 2012-05-21 | 2013-05-21 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9526760B2 (enExample) |
| EP (1) | EP2852399B1 (enExample) |
| JP (2) | JP6632376B2 (enExample) |
| CN (2) | CN110054677A (enExample) |
| AU (1) | AU2013266468B2 (enExample) |
| BR (1) | BR112014028951A8 (enExample) |
| CA (1) | CA2873771A1 (enExample) |
| DK (1) | DK2852399T3 (enExample) |
| ES (1) | ES2791251T3 (enExample) |
| IN (1) | IN2014MN02461A (enExample) |
| RU (1) | RU2617964C2 (enExample) |
| WO (1) | WO2013177198A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013266468B2 (en) * | 2012-05-21 | 2017-11-09 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
| US11793758B2 (en) | 2018-06-22 | 2023-10-24 | Bioralix B.V. | Formulations of biological polymers for oral administration |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
| US4469689A (en) | 1983-03-30 | 1984-09-04 | The Upjohn Company | Sulfonate containing ester prodrugs of corticosteroids |
| US6750052B1 (en) | 1997-07-23 | 2004-06-15 | The Brigham And Women's Hospital, Inc. | Lens epithelial cell derived growth factor |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1562627A4 (en) | 2002-08-23 | 2006-11-02 | Mclean Hospital Corp | CORTICOSTEROID CONJUGATES AND ITS USES |
| AU2003273633A1 (en) * | 2002-09-26 | 2004-04-19 | K.U.Leuven Research And Development | Integrase cofactor |
| AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| US20060166879A1 (en) | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| JP2008512984A (ja) * | 2004-05-28 | 2008-05-01 | ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌の同定、評価、予防および治療のための組成物、キットおよび方法 |
| EP1971288B1 (en) | 2005-12-30 | 2013-02-13 | Neurotech USA, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008053478A2 (en) | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| US8168393B2 (en) * | 2007-02-16 | 2012-05-01 | The Brigham And Women's Hospital, Inc. | Compositions and methods for diagnosing tumors using LEDGF/p75 |
| JP5616336B2 (ja) * | 2008-06-26 | 2014-10-29 | オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ | 酵素活性の調節因子としてのＨｓｐ７０の使用 |
| GB0812742D0 (en) * | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| US10234453B2 (en) * | 2011-07-01 | 2019-03-19 | Inova Diagnostics, Inc. | Method for increasing specificity of diagnostic tests for autoimmune diseases |
| AU2013266468B2 (en) * | 2012-05-21 | 2017-11-09 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
-
2013
- 2013-05-21 AU AU2013266468A patent/AU2013266468B2/en active Active
- 2013-05-21 CN CN201811628163.9A patent/CN110054677A/zh active Pending
- 2013-05-21 DK DK13794410.4T patent/DK2852399T3/da active
- 2013-05-21 WO PCT/US2013/042074 patent/WO2013177198A1/en not_active Ceased
- 2013-05-21 IN IN2461MUN2014 patent/IN2014MN02461A/en unknown
- 2013-05-21 EP EP13794410.4A patent/EP2852399B1/en active Active
- 2013-05-21 JP JP2015514127A patent/JP6632376B2/ja not_active Expired - Fee Related
- 2013-05-21 BR BR112014028951A patent/BR112014028951A8/pt not_active IP Right Cessation
- 2013-05-21 RU RU2014151603A patent/RU2617964C2/ru active
- 2013-05-21 CA CA2873771A patent/CA2873771A1/en not_active Abandoned
- 2013-05-21 ES ES13794410T patent/ES2791251T3/es active Active
- 2013-05-21 US US14/402,426 patent/US9526760B2/en active Active
- 2013-05-21 CN CN201380038504.6A patent/CN104470534A/zh active Pending
-
2016
- 2016-11-10 US US15/348,970 patent/US10221226B2/en active Active
-
2018
- 2018-05-23 JP JP2018098420A patent/JP2018172386A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104470534A (zh) | 2015-03-25 |
| WO2013177198A1 (en) | 2013-11-28 |
| US9526760B2 (en) | 2016-12-27 |
| EP2852399B1 (en) | 2020-02-19 |
| JP2018172386A (ja) | 2018-11-08 |
| EP2852399A1 (en) | 2015-04-01 |
| AU2013266468B2 (en) | 2017-11-09 |
| DK2852399T3 (da) | 2020-05-04 |
| US20170129929A1 (en) | 2017-05-11 |
| JP2015519343A (ja) | 2015-07-09 |
| AU2013266468A1 (en) | 2014-12-18 |
| BR112014028951A8 (pt) | 2021-09-14 |
| US10221226B2 (en) | 2019-03-05 |
| CA2873771A1 (en) | 2013-11-28 |
| RU2617964C2 (ru) | 2017-04-28 |
| US20150147404A1 (en) | 2015-05-28 |
| CN110054677A (zh) | 2019-07-26 |
| RU2014151603A (ru) | 2016-07-10 |
| JP6632376B2 (ja) | 2020-01-22 |
| ES2791251T3 (es) | 2020-11-03 |
| BR112014028951A2 (pt) | 2017-07-25 |
| EP2852399A4 (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273107B (en) | Pharmaceutical preparations of human rpe cells and their use | |
| IL260585B (en) | Compositions and methods for treating retinal diseases | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| ZA201408119B (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
| IL236920B (en) | Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| WO2013005053A3 (en) | Progenitor cells of mesodermal lineage | |
| HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| PL2717914T3 (pl) | Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania | |
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| MY185108A (en) | Method for treatment of labor arrest | |
| PH12015500663A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| MX356727B (es) | Formulaciones de liberacion modificada de viloxacina. | |
| HK1203369A1 (en) | Combination treatment comprising sulphated glycosaminoglycans for inducing labor | |
| MX368943B (es) | Formulaciones de tripeptido liofilizado estables en almacenamiento. | |
| WO2013190509A3 (en) | Preparation of intermediates of boceprevir | |
| BR112014028951A2 (pt) | peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| CA2864049A1 (en) | Use of beta-nerve growth factor for inducing ovulation in mammals | |
| UA97741C2 (ru) | Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами | |
| WO2013042156A3 (en) | Peptides having protective effect towards the inflammatory activity of peptide 31-43 of a-gliadin in celiac disease |